Reactive Robotics builds robots for the early clinical mobilization of intensive care patients. With a seven-figure investment, the company continues its path toward market launch.
The Munich-based startup Reactive Robotics has secured a seven-figure investment sum. The money comes from existing investors Bayern Kapital, the TQ Group, and MedTech Innovation Partners (MTIP). High-Tech Gründerfonds (HTGF) remains on board as a shareholder. The existing investor consortium was expanded in the current financing round to include Dr. Doll Holding GmbH as the new lead investor. The startup aims to use the fresh capital to accelerate its market entry and internationalization.
Robots should help patients
Reactive Robotics is developing an intelligent assistance system that supports the early mobilization of intensive care patients. Patients can be expertly moved with the help of robots as early as 24 hours after admission to the hospital. This should enable a faster recovery. The goal of the company, founded in 2015, is to use its devices to become the standard of care for early mobilization.
The devices developed by Reactive Robotics are connected directly to the patient's bedside, saving patients the risk of transferring to other therapy devices. Furthermore, their ease of use should reduce the workload for therapists and nursing staff.
The startup estimates the volume of the market it serves to be over two billion euros.
Dr. Georg Ried, Managing Director of Bayern Kapital, says:
"The positive development and innovative system solution of Reactive Robotics made it easy for us to decide to pursue follow-up financing. Since our initial investment, the company has made significant progress in prototype development, quality management, and collaboration with partners and suppliers."
Dr. Alexander König, Managing Director and Founder of Reactive Robotics, says:
"We have established many contacts with physicians and healthcare experts, allowing us to further develop our system solution in a way that is application-oriented. Our goal is clear: We want to achieve clinical validation of our device as soon as possible. Our investors are helping us to further advance our business development and remain focused on our ambitious timeline."
